You just read:

Alopexx Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society Of Hematology Annual Meeting

News provided by

Alopexx Oncology, LLC

06 Dec, 2016, 16:54 ET